Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline – - In people with AMKD and type 2 diabetes, treatment with inaxaplin led to a reduction in UACR of -17.3% at Week 13 — Company newsroom — sourced from Vertex Pharmaceuticals. Matter furnished by the company. Not a Notice Nearby paid placement. This page reprints a substantial excerpt from the official release. Read the original for the full text. Read the original: https://investors.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study